Estudio sobre la variabilidad de los protocolos de quimioterapia en cancer de ovario en 10 hospitales Españoles

• Autores: Javier Merino Alonso, Fernando Piedra Sánchez, M. A. Velaz Suárez, R. Luque Infante, A. Barrio Gil-Fournier
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 6, Nº. 2, 2004, págs. 89-96
• Idioma: español
• Títulos paralelos:
  • Study about the variability of chemotherapy's protocols in ovarian cancer in 10 Spanish hospitals
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To determine the variability of chemotherapy schemes used in the treatment of ovarian cancer. Method: In 10 Spanish hospitals, the chemotherapy schemes usually prescribed for the treatment of ovarian cancer were recorded. It was considered the variability, any difference in the cytostatics' dosage or their order of administration. Results: 56 records were obtained. For each scheme, it was calculated the variability index according to the equation: no. variations-1/total no. of scheme records × 100. The following results were obtained: paclitaxel + carboplatin (36.4%), paclitaxel + cisplatin (66.7%), liposomal doxorubicin (37.5%), topotecan (14.3%), cyclophosphamide + cisplatin (50%), monotherapy paclitaxel, monotherapy paclitaxel (66.7%) and gemcitabine (0%). Conclusions: The observed high variability implies that the selection criteria for each scheme differ among hospitals. It is necessary a systematic revision of the scientific literature and a consensus among oncologists in order to establish a reference treatment for every studied scheme, based on efficacy and safety data